Training and ‘sea turtles’ support WuXi Biologics’ growing China footprint
WuXi Biologics talks Chinese talent recruitment as it begins building an eighth biomanufacturing facility in the country, this one with 48,000 L of single-use bioreactor capacity. The latest addition to contract development and manufacturing organization (CDMO) WuXi Biologics’ bioproduction net ...
Bioprocessing vendor Repligen will add eight manufacturing suites to keep ahead of demand for its large-scale OPUS prefilled chromatography colum ...
The US FDA has published long-awaited final guidance on the interchangeability of biologics, calling biosimilar developers to carry out switching ...
The combination of cold-chain logistics and biostorage places Cryoport in good stead for the arrival of allogeneic cell therapies, an analyst say ...
Neither a CDMO nor an end-user, ElevateBio is looking to change the paradigm in cell and gene therapy development through it’s a centralized R& ...
Recent Tweets
-
Training and ‘sea turtles’ support WuXi Biologics China footprint https://t.co/uAPe8rTlho https://t.co/PoHnHZOlJE
1 hour ago
-
RT @Dan5tanton: Bioprocessing vendor @Repligen will add eight manufacturing suites to keep ahead of demand for its large-scale OPUS… https://t.co/XcBNUmo0kB
5 hours ago
-
RT @Dan5tanton: Another biomanufacturing investment in by WuXi Biologics in native China. But how will #CDMO staff these facilities… https://t.co/jw7KrnnEi1
3 days ago
-
And a heck of a headline to boot! https://t.co/rU6KXg1NMj
5 days ago
